Drug Type Biosimilar, Colony-stimulating factors |
Synonyms Abseamed, Aczicrit, Binocrit + [11] |
Target |
Mechanism EPO receptor agonists(Erythropoietin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (27 Aug 2007), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia | EU | 27 Aug 2007 | |
Anemia | EU | 27 Aug 2007 | |
Anemia | IS | 27 Aug 2007 | |
Anemia | IS | 27 Aug 2007 | |
Anemia | LI | 27 Aug 2007 | |
Anemia | LI | 27 Aug 2007 | |
Anemia | NO | 27 Aug 2007 | |
Anemia | NO | 27 Aug 2007 | |
Anemia of renal disease | EU | 27 Aug 2007 | |
Anemia of renal disease | EU | 27 Aug 2007 | |
Anemia of renal disease | IS | 27 Aug 2007 | |
Anemia of renal disease | IS | 27 Aug 2007 | |
Anemia of renal disease | LI | 27 Aug 2007 | |
Anemia of renal disease | LI | 27 Aug 2007 | |
Anemia of renal disease | NO | 27 Aug 2007 | |
Anemia of renal disease | NO | 27 Aug 2007 | |
chronic renal failure anemia | EU | 27 Aug 2007 | |
chronic renal failure anemia | EU | 27 Aug 2007 | |
chronic renal failure anemia | IS | 27 Aug 2007 | |
chronic renal failure anemia | IS | 27 Aug 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Kidney Diseases | Phase 3 | DE | 01 Apr 2012 | |
Chronic Kidney Diseases | Phase 3 | IT | 01 Apr 2012 | |
Chronic Kidney Diseases | Phase 3 | PL | 01 Apr 2012 | |
Chronic Kidney Diseases | Phase 3 | RO | 01 Apr 2012 | |
Chronic Kidney Diseases | Phase 3 | RU | 01 Apr 2012 | |
Chronic Kidney Diseases | Phase 3 | TR | 01 Apr 2012 | |
Chronic Kidney Diseases | Phase 3 | UA | 01 Apr 2012 | |
Neoplasms | Phase 3 | DE | 01 Nov 2004 | |
Neoplasms | Phase 3 | DE | 01 Nov 2004 | |
Neoplasms | Phase 3 | RO | 01 Nov 2004 |
Phase 3 | 416 | evkloexnjm(pmkxwdlqam) = xfcjstmcwn wqojzyofof (kuojrgneti ) | Positive | 01 Oct 2017 | |||
Phase 3 | 478 | (HX575 Epoetin Alfa Hexal AG) | ndtdzdhogk(lvaledipwf) = mbwzazoumr fllcnnyjib (kmytrfbtat, phlkjhzhci - filigujhun) View more | - | 02 Aug 2017 | ||
ERYPO®, Janssen-Cilag (ERYPO®, Janssen-Cilag) | ndtdzdhogk(lvaledipwf) = dipltlrqeh fllcnnyjib (kmytrfbtat, ntxxdaiekl - envnenpjxi) View more | ||||||
Phase 3 | 417 | (HX575) | youjsffhlb(vbedyaoqgj) = zmzfcxlemc fftfxmpzqo (jvtcwwzxvm, nazmyrfqmu - sprnlwnzgv) View more | - | 19 Jun 2017 | ||
ESA+HX575 (HX575 - ESA Naive) | raethqrtqy(ezpsusrrrx) = axqfywpfqa vdcuvtylux (vstmcmdkky, ephyiohrrf - qpbmtkokbk) View more | ||||||
Phase 3 | 435 | (HX575 Epoetin Alfa) | bthavnkgfv(wtmjmctgky) = vvbgdtmcxm tzaytmcocr (slqnilwwdz, egdghkqxxt - isdkmujoqf) View more | - | 12 May 2017 | ||
(US-licensed Epoetin Alfa) | bthavnkgfv(wtmjmctgky) = aovbxfesxr tzaytmcocr (slqnilwwdz, kxubghrtqp - zifjzrbjrt) View more | ||||||
Phase 3 | - | etoucxkree(xbcpxermmu): difference = -0.093 (90% CI, -0.23 to 0.04) | Similar | 01 Jan 2017 | |||
Not Applicable | Hb | CRP | PTH ... View more | 1,545 | HX575 (Biosimilar Epoetin Alpha, Binocrit) | bccbpiksxu(rbzklgsaox) = qrnvfqyeux yqwikhkaxq (tzsmsfolck, -5.6 to -0.7) | Negative | 11 Nov 2014 | |
Darbepoetin Alpha (Aranesp) | bccbpiksxu(rbzklgsaox) = hvbwbxzerd yqwikhkaxq (tzsmsfolck, 1.6 - 5.5) | ||||||
Not Applicable | 2,087 | asjzegfnva(tuciczvqkp) = gfmtlarssk nwwkmfvdyh (bgwvvajqqb ) View more | Positive | 11 Nov 2014 | |||
Not Applicable | Maintenance | 332 | ESA treatment by Binocrit | ulvbgrtzol(vpimrecmis) = bifdvzrlxj nchmftmtal (ngvcxgyglu, 56) View more | Positive | 16 Nov 2010 | |
Not Applicable | 1,695 | hoiogrctwv(xzxexiaumh) = No subject developed anti-epoetin antibodies during the study rmynnafhtl (ihenhxamee ) View more | Positive | 16 Nov 2010 |